Sevel400 mg

Sevel is a non-calcium, non-metal phosphate-binding agent primarily used in the management of hyperphosphatemia (elevated blood phosphorus) in patients with chronic kidney disease (CKD).

Established / FDA-approved use

• Control of serum phosphorus levels in adult patients with chronic kidney disease who are on dialysis (hemodialysis or peritoneal dialysis).

Guideline-supported / broader nephrology use

• Some patients with advanced CKD not yet on dialysis (CKD stage 4-5) are managed with Sevel as part of an overall phosphorus-control strategy, guided by nephrology assessment and local guidelines, alongside dietary phosphate restriction.

Sevel does not treat the underlying kidney disease itself; it is used as part of a broader chronic kidney disease/dialysis management plan that also requires regular monitoring of serum phosphorus and calcium by the treating nephrology team.

Each tablet/capsule contains Sevelamer Hydrochloride as the active ingredient, formulated as an oral, non-absorbed, cross-linked polymer for oral administration.

Sevel is a synthetic, cross-linked polymer that acts as a phosphate binder. It is not absorbed from the gastrointestinal tract and works locally within the gut to bind dietary phosphate, reducing the amount of phosphate available for absorption into the bloodstream.

Sevel is used specifically in patients with chronic kidney disease, particularly those undergoing dialysis, whose kidneys can no longer adequately excrete excess phosphorus.

Sevel belongs to the class of phosphate-binding agents (non-calcium, non-aluminum phosphate binders), used in the management of hyperphosphatemia in chronic kidney disease.

Sevelamer Hydrochloride is a polymeric amine that is not absorbed systemically. Within the gastrointestinal tract, its multiple amine groups become protonated and bind dietary phosphate through ionic and hydrogen bonding, forming a complex that is excreted in the feces.

By binding phosphate in the gut, Sevelamer Hydrochloride reduces the amount of phosphate absorbed into the bloodstream, thereby lowering serum phosphorus concentrations. Because it acts locally in the gut and is not systemically absorbed, no dose adjustment is typically required based on renal or hepatic function.

Sevel tablets should be taken by mouth with meals, swallowed whole with liquid, and never crushed or chewed; see Dosage and Administration for complete instructions.

Sevel can reduce the absorption of certain oral medications and fat-soluble vitamins if taken at the same time, because it binds substances non-selectively in the gastrointestinal tract.

• Ciprofloxacin: Sevel reduces ciprofloxacin absorption; ciprofloxacin should be taken at least 2 hours before or 6 hours after Sevel.
• Mycophenolate mofetil, cyclosporine, tacrolimus (immunosuppressants): reduced absorption possible; dosing should be separated and levels monitored, particularly important due to narrow therapeutic index of these agents.
• Levothyroxine: reduced absorption reported; separate administration times and monitor thyroid function.
• Fat-soluble vitamins (A, D, E, K): Sevel may reduce absorption of these vitamins with chronic use; patients on dialysis should have vitamin status monitored, and supplementation considered if needed.

As a general precaution, oral medications with a narrow therapeutic index or for which reduced absorption would be clinically significant should be taken at least 1 hour before or 3 hours after Sevel, unless otherwise directed by the physician.

The most common side effects of Sevel involve the gastrointestinal system and can be significant, especially with higher pill burden:

• Nausea and vomiting
• Dyspepsia (indigestion)
• Diarrhea
• Constipation
• Abdominal pain/bloating

Rare but serious effects include bowel obstruction or impaction, particularly in patients with pre-existing gastrointestinal motility disorders, prior gastrointestinal surgery, or other gastrointestinal risk factors. Patients should seek prompt medical attention for severe abdominal pain, inability to pass stool, or persistent vomiting.

Data on the use of Sevel in pregnancy are limited. Sevel is not systemically absorbed, which may limit direct fetal exposure, but it should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

It is not known whether Sevel affects breastfed infants, since the drug itself is not absorbed; however, due to its effect on absorption of fat-soluble vitamins and other nutrients in the mother, use during breastfeeding should be discussed with a physician, and the nursing mother's vitamin status should be monitored.

• Sevel must be taken with meals; it is not effective if taken apart from food.
• Gastrointestinal side effects are common; report severe or worsening abdominal pain, constipation, or inability to pass stool/gas promptly, as these may indicate bowel obstruction (see Contraindications and Side Effects).
• Use with caution in patients with gastrointestinal motility disorders, active inflammatory bowel disease, major gastrointestinal tract surgery, or significant swallowing disorders/dysphagia, due to increased risk of obstruction.
• Sevel may reduce absorption of certain co-administered oral medications and fat-soluble vitamins; dosing separation may be needed (see Interactions).
• Sevel does not treat the underlying kidney disease; it is used as part of a comprehensive chronic kidney disease/dialysis management plan requiring regular monitoring of serum phosphorus and calcium by the treating nephrology team.
• Do not stop, skip, or change the dose of Sevel without medical advice, since phosphorus control requires consistent, physician-guided dosing.

There is limited clinical experience with overdose of Sevel. In case of a suspected overdose, seek immediate medical attention or contact emergency services/a poison control center. Symptoms, if they occur, would most likely relate to gastrointestinal effects. Management would be supportive and symptomatic under medical supervision; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

Sevel is specifically indicated for use in patients with chronic kidney disease, particularly those on dialysis; no additional dose adjustment based on renal function is required beyond standard phosphorus-guided titration, since the drug is not systemically absorbed.

Hepatic impairment

No specific dose adjustment is established for hepatic impairment, given the lack of systemic absorption.

Elderly

No specific dose adjustment is required based on age alone; elderly patients should be monitored for gastrointestinal tolerance and adequate hydration.

Pediatric patients

Safety and efficacy have not been well established in pediatric patients; use only under close nephrology supervision if considered necessary.

Sevel is typically used long-term/chronically for as long as the patient requires phosphorus control related to chronic kidney disease or dialysis, with the dose adjusted periodically based on serum phosphorus monitoring by the treating physician.

Phosphate binder (non-calcium, non-aluminum, non-absorbed polymeric phosphate binder).

Sevelamer Hydrochloride works by binding dietary phosphate within the gastrointestinal tract through its amine groups, forming a non-absorbable complex that is eliminated in the feces, thereby lowering serum phosphorus levels without being systemically absorbed itself.

C

Safety and efficacy of Sevel have not been well established in pediatric patients. Use in children should occur only under close nephrology supervision when the treating physician determines it is necessary, with careful monitoring of growth, nutrition, and serum phosphorus/calcium levels.